Literature DB >> 24251815

Homoarginine and mortality in an older population: the Hoorn study.

Stefan Pilz1, Tom Teerlink, Peter G Scheffer, Andreas Meinitzer, Femke Rutters, Andreas Tomaschitz, Christiane Drechsler, Katharina Kienreich, Giel Nijpels, Coen D A Stehouwer, Winfried März, Jacqueline M Dekker.   

Abstract

BACKGROUND: Homoarginine is an amino acid that may be involved in nitric oxide and energy metabolism. Previous studies in patient populations showed that low homoarginine levels indicate an increased risk of mortality and cardiovascular disease. We evaluated whether low plasma levels of homoarginine are associated with elevated, overall and cause-specific mortality.
MATERIALS AND METHODS: The Hoorn study is a population-based study among older men and women. We calculated Cox proportional hazard ratios (HRs) for overall and cause-specific mortality according to sex-specific homoarginine quartiles.
RESULTS: We included 606 study participants (51·3% women; 70·0 ± 6·6 years). Homoarginine concentrations were higher in men (1·63 ± 0·51 μM), compared with women (1·30 ± 0·44 μM; P < 0·001). After a median follow-up time of 7·8 years, 112 study participants died, including 31 deaths due to cardiovascular diseases and 30 due to cancer. Associations between homoarginine levels and mortality showed a threshold effect with a significant risk increase from the second to the first quartile. Compared with the upper three quartiles, the age-, sex- and BMI-adjusted HR (with 95% CI) in the first quartile was 2·26 (1·52-3·32) for overall mortality, 4·20 (2·03-8·69) for cardiovascular mortality and 1·25 (0·55-2·85) for cancer mortality. These associations remained materially unchanged after multivariate adjustments.
CONCLUSIONS: Low plasma concentrations of homoarginine are a risk marker for overall mortality and especially for cardiovascular mortality in the older general population. Further studies are warranted to elucidate the underlying pathophysiological mechanisms.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  AMINO acids; cardiovascular; homoarginine; mortality; prospective

Mesh:

Substances:

Year:  2013        PMID: 24251815     DOI: 10.1111/eci.12208

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  13 in total

1.  Oral supplementation with L-homoarginine in young volunteers.

Authors:  Dorothee Atzler; Mirjam Schönhoff; Kathrin Cordts; Imke Ortland; Julia Hoppe; Friedhelm C Hummel; Christian Gerloff; Ulrich Jaehde; Annika Jagodzinski; Rainer H Böger; Chi-Un Choe; Edzard Schwedhelm
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

2.  The biomarker and causal roles of homoarginine in the development of cardiometabolic diseases: an observational and Mendelian randomization analysis.

Authors:  Ilkka Seppälä; Niku Oksala; Antti Jula; Antti J Kangas; Pasi Soininen; Nina Hutri-Kähönen; Winfried März; Andreas Meinitzer; Markus Juonala; Mika Kähönen; Olli T Raitakari; Terho Lehtimäki
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

3.  Association of Lower Plasma Homoarginine Concentrations with Greater Risk of All-Cause Mortality in the Community: The Framingham Offspring Study.

Authors:  Edzard Schwedhelm; Rebecca J Song; Ramachandran S Vasan; Edwin R van den Heuvel; Juliane Hannemann; Vanessa Xanthakis; Rainer Böger
Journal:  J Clin Med       Date:  2020-06-26       Impact factor: 4.241

4.  Low-Circulating Homoarginine is Associated with Dilatation and Decreased Function of the Left Ventricle in the General Population.

Authors:  Martin Bahls; Dorothee Atzler; Marcello R P Markus; Nele Friedrich; Rainer H Böger; Henry Völzke; Stephan B Felix; Edzard Schwedhelm; Marcus Dörr
Journal:  Biomolecules       Date:  2018-07-30

5.  The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.

Authors:  Emir Taghikhani; Renke Maas; Martin F Fromm; Jörg König
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

6.  l-Homoarginine supplementation prevents diabetic kidney damage.

Authors:  Michael D Wetzel; Ting Gao; Manjeri Venkatachalam; Sidney M Morris; Alaa S Awad
Journal:  Physiol Rep       Date:  2019-09

7.  Vectorial transport of the arginine derivatives asymmetric dimethylarginine (ADMA) and L-homoarginine by OATP4C1 and P-glycoprotein studied in double-transfected MDCK cells.

Authors:  Emir Taghikhani; Renke Maas; R Verena Taudte; Arne Gessner; Martin F Fromm; Jörg König
Journal:  Amino Acids       Date:  2020-07-08       Impact factor: 3.520

Review 8.  Modular organization of cardiac energy metabolism: energy conversion, transfer and feedback regulation.

Authors:  R Guzun; T Kaambre; R Bagur; A Grichine; Y Usson; M Varikmaa; T Anmann; K Tepp; N Timohhina; I Shevchuk; V Chekulayev; F Boucher; P Dos Santos; U Schlattner; T Wallimann; A V Kuznetsov; P Dzeja; M Aliev; V Saks
Journal:  Acta Physiol (Oxf)       Date:  2014-04-18       Impact factor: 6.311

9.  Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain.

Authors:  Dorothee Atzler; Christina Baum; Francisco Ojeda; Till Keller; Kathrin Cordts; Renate B Schnabel; Chi-un Choe; Karl J Lackner; Thomas Münzel; Rainer H Böger; Stefan Blankenberg; Edzard Schwedhelm; Tanja Zeller
Journal:  J Am Heart Assoc       Date:  2016-04-13       Impact factor: 5.501

10.  Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance.

Authors:  S Tommasi; D J Elliot; M Da Boit; S R Gray; B C Lewis; A A Mangoni
Journal:  Sci Rep       Date:  2018-02-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.